Securing clinical study reports ahead of submission

An innovative biopharmaceutical player, this company develops immuno-inflammation therapies across several clinical programmes, including a product in late phase 3 heading for a marketing authorisation submission in the near term. That deadline marks a sharp acceleration of activity.

The production of the scientific deliverables required by regulators becomes decisive: the quality and speed of the documents condition the milestones. The company has to absorb this peak load without disrupting its internal teams.

An interim manager with an advanced scientific background and solid medical writing practice in biopharmaceutical environments works for one month, remotely: finalising and securing several clinical study reports within tight deadlines, guaranteeing the scientific quality and regulatory compliance of the deliverables ahead of submission, and absorbing a peak load without disturbing the internal teams. Their knowledge of late-stage programmes and feel for immunology bring senior expertise that is immediately deployable.